Stephen D. Silberstein

TL;DR: The International Classification of Headache Disorders, 3 edition (beta version), may be reproduced freely for scientific, educational or clinical uses by institutions, societies or individuals as mentioned in this paper. But the authors require the permission of the International Headache Society.

TL;DR: This practice parameter summarizes the results from the four evidence-based reviews on the management of patients with migraine: specifically, acute, preventive, and nonpharmacologic treatments for migraine, and the role of neuroimaging in patients with headache.

TL;DR: The International Headache Classification Committee has worked out the more inclusive criteria for CM and MOH and it is now recommended that the MOH diagnosis should no longer request improvement after discontinuation of medication overuse but should be given to patients if they have a primary headache plus ongoing medication over use.

TL;DR: Significant reductions from baseline were observed for onabotulinumtoxinA for headache and migraine days, cumulative hours of headache on headache days and frequency of moderate/severe headache days, which in turn reduced the burden of illness in adults with disabling chronic migraine.

TL;DR: OnabotulinumtoxinA (BOTOX®) as discussed by the authors is an effective prophylactic treatment for chronic migraine in adults with chronic migraines and showed significant improvements compared with placebo in multiple headache symptom measures and significantly reduced headache-related disability and improved functioning, vitality, and overall health-related quality of life.